To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ...

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

Bristol Myers Squibb Co. closed 6.61% short of its 52-week high of $61.08, which the company reached on November 11th.

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...

Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.

Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and ...